Cyrus Biotechnology Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cyrus Biotechnology Inc. - overview
Established
2014
Location
Seattle, WA, US
Primary Industry
Software
About
Founded in 2014 and based in Washington, US, Cyrus Biotechnology Inc. operates as a software company that offers a biologics discovery platform. The company was founded by David Baker. In December 2021, Cyrus Biotechnology Inc.
raised USD 18 million in Series B funding from Agent Capital, Select Fund Management, Selecta Biosciences, Inc. , and The Yard Ventures. As of 2023, the company is led by its CEO, Lucas Nivon. Cyrus Biotechnology’s product line includes Cyrus Bench, which is a Rosetta-based protein design software that consists of a molecular modeling and design toolkit to solve protein engineering and structure prediction problems with the help of artificial intelligence; Cyrus API, which is a cloud-based platform for computational modeling and bioinformatics; deimmunization, a machine learning-based protein design platform for eliminating the immunogenicity of therapeutic proteins; and Cyrus’s protein biochemistry platform that uses deep mutational scanning and selection to explore the mutational landscape of proteins.
The firm’s pipeline portfolio includes CRISPR (clustered, regularly interspaced short palindromic repeats), a bacterial enzyme system; ACE2, which is a protein-based therapeutic for COVID-19; and a treg-selective IL-2 protein agonist (IL-2).
Current Investors
OrbiMed Advisors, Trinity Ventures, The W Fund
Primary Industry
Software
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics, Application Integration Software, Medical Software
Website
www.cyrusbio.com
Verticals
Artificial Intelligence, Big Data, Cloud Computing, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Cyrus Biotechnology Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.